Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of GenSci164 in Healthy Adult Participants in China

NCT07790783 is registered in ClinicalTrials.gov with Changchun GeneScience Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07790783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07790783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of GenSci164 in Healthy Adult Participants in China
Lead sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 24, 2026
Completion date
February 28, 2028
Enrollment
56 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult trial participants